A MEDICINE COMPANY


ELI LILLY AND COMPANY
Q1 2025 EARNINGS CALL



Agenda

Introduction and Key Events
Dave Ricks, Chair and Chief Executive Officer

Q1 2025 Financial Results
Lucas Montarce, Chief Financial Officer

R&D Update
Dan Skovronsky, M.D., Ph.D., Chief Scientific Officer

Closing Remarks
Dave Ricks, Chair and Chief Executive Officer

Question & Answer Session

Safe Harbor Provision and Other Information

This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including healthcare reform.

For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. Certain financial information in this presentation is presented on a non-GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's non-GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP. These materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated.

The company undertakes no duty to update forward-looking statements except as required by applicable law.

Q1 2025 Summary

Deliver Revenue Growth

Delivered robust **revenue growth of 45%** driven by **Key Products**[1]

Gained U.S. incretin analogs **market leadership**, with **53.3% share of market** in total prescriptions

Reaffirmed **2025 Revenue Guidance of $58.0B to $61.0B**

Invest in Future Innovation

Announced plans to **double U.S. manufacturing investments** to a total of **$50B** committed since 2020

Closed acquisition of **Scorpion Therapeutics' mutant selective PI3Kα inhibitor** program

Speed Life-Changing Medicines

Disclosed **first positive Phase 3 trial for oral GLP-1, orforglipron**

Orforglipron demonstrated **statistically significant efficacy results** and a **safety profile consistent with injectable GLP-1 medicines**

[1] Key products include Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound
Note: Revenue growth rates reflect change vs. Q1 2024

Strategic Deliverables

Deliver Revenue Growth

TOTAL REVENUE **$12.7B** 45% ⬆

KEY PRODUCT REVENUE **$7.5B** 119% ⬆

Invest in Future Innovation

RESEARCH & DEVELOPMENT

$2.7B

8% ⬆

CAPITAL INVESTMENTS

$50B

Committed U.S. manufacturing investments since 2020

Invest in Current Portfolio

MARKETING, SELLING & ADMINISTRATIVE **$2.5B** 26% ⬆

NON-GAAP EARNINGS PER SHARE **$3.34** 29% ⬆

Speed Life-Changing Medicines

APPROVALS / LAUNCHES

- **Jaypirca approved in the EU for relapsed or refractory CLL patients previously treated with a BTK inhibitor**
- **Launched 7.5 mg and 10.0 mg single-dose Zepbound vials exclusively through LillyDirect**

STUDY RESULTS

- **Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in a successful Phase 3 trial**
- **Lilly's EBGLYSS single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis**

Return Capital to Shareholders

$1.3B DISTRIBUTED VIA DIVIDENDS

$1.2B DISTRIBUTED IN SHARE REPURCHASES

Note: Total revenue, key product revenue, research and development, marketing, selling and administrative, and Non-GAAP EPS growth rates reflect change vs. Q1 2024

Q1 Key Income Statement Measures (unaudited)

Dollars in millions; except per share data

Q1 2025

	GAAP Reported	Adjustments	Non-GAAP Adjusted	YoY Non-GAAP Adjusted Change
TOTAL REVENUE	**$12,729**	$ –	**$12,729**	45%
GROSS MARGIN	**82.5%**	1.0pp	**83.5%**	1.0pp
TOTAL OPERATING EXPENSE	**$6,809**	$(35)	**$6,774**	48%
OPERATING INCOME	**$3,695**	$158	**$3,853**	46%
OTHER INCOME (EXPENSE)	**$(239)**	$152	**$(87)**	NM
EFFECTIVE TAX RATE	**20.2%**	--	**20.2%**	8.3pp
NET INCOME	**$2,759**	$245	**$3,004**	29%
EPS	**$3.06**	$0.28	**$3.34**	29%
Acquired IPR&D Charge per share[1]	**$1.72**	**$ -**	**$1.72**	**NM**

[1]Acquired IPR&D (in-process research and development) charge of $1,572 million (pre-tax). Numbers may not add due to rounding; NM = not meaningful

Performance Margin[2]	**41.4%**		**42.6%**	**+11.1pp**

[2]The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative, and asset impairment, restructuring and other special charges divided by revenue
Note: The Non-GAAP Performance Margin excludes the amortization of intangible assets. The applicable impact of amortization of intangible assets can be found in the reconciliation tables on slide 20

Price/Rate/Volume Effect on Revenue

Dollars in millions

Q1 2025

	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$8,489	(7)%	-	57%	49%	49%
EUROPE	$2,389	(7)%	(6)%	79%	66%	71%
JAPAN	$402	(1)%	(5)%	16%	11%	15%
CHINA	$451	2%	(1)%	19%	20%	21%
REST OF WORLD	$997	1%	(5)%	16%	12%	17%
TOTAL REVENUE	**$12,729**	**(6)%**	**(2)%**	**53%**	**45%**	**47%**

Numbers may not add due to rounding

CER = price change + volume change

Q1 2025 Update on Key Products



Key Product Highlights:

MOUNJARO
U.S. type 2 diabetes incretin analogs TRx SOM 39% and NBRx SOM 46% at end of Q1 2025

Increased TRx and NBRx share by 4pp each vs. end of Q4 2024

ZEPBOUND
U.S. branded anti-obesity TRx SOM over 60% and NBRx SOM 74% at end of Q1 2025

Increased TRx and NBRx share by 13pp and 17pp, respectively, vs. end of Q4 2024

VERZENIO
U.S. TRx SOM 43% at end of Q1 2025
U.S. TRx grew 7% vs. Q1 2024

JAYPIRCA
Q1 2025 sales of $92 million and achieved regulatory approval for relapsed or refractory CLL after a BTK inhibitor in the EU

EBGLYSS
Q1 2025 sales of $60M and 1st line formulary access secured at 2 of the major PBMs in the U.S.

OMVOH
Approval and launch of Crohn's disease in Q1 2025

KISUNLA
Q1 2025 sales increased to $21 million

Not for promotional use

U.S. Incretin Analogs Market



Source: IQVIA weekly NPA total prescriptions, weekly data March 28, 2025; Incretin analogs market includes: injectable GLP-1s, oral GLP-1s and GLP-1/GIP dual agonists

Incretin Analogs Market Key Highlights:

Total prescriptions grew 46% in Q1 vs. prior year and 5% vs. Q4 2024

Lilly share of market increased to 53.3%, +5pp vs. prior quarter

Launched 7.5 mg and 10.0 mg single-dose Zepbound vials exclusively through LillyDirect

Capital Allocation

$ in billions

Q1 2025 Capital Allocation



* After tax

** Includes development milestones, closed acquisitions and cash outflows associated with equity investments

2025 Guidance

	Prior	Updated	Comments
REVENUE	$58.0 – $61.0 billion	Unchanged	
PERFORMANCE MARGIN[1]			
(GAAP)	40.5% – 42.5%	Unchanged	
(NON-GAAP)	41.5% – 43.5%	Unchanged	
OTHER INCOME/(EXPENSE)			
(GAAP)	$(700) – $(600) million	$(850) – $(750) million	Driven by net losses on investments in equity securities
(NON-GAAP)	$(700) – $(600) million	Unchanged	
TAX RATE	Approx. 16%	Approx. 17%	Driven by the tax impact of the non-deductible acquired IPR&D charge incurred in Q1
EARNINGS PER SHARE[2]			
(GAAP)	$22.05 – $23.55	$20.17 – $21.67	No changes to non-GAAP EPS, outside of Q1 acquired IPR&D charge of $1.72 per share
(NON-GAAP)	$22.50 – $24.00	$20.78 – $22.28	

[1] The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative and asset impairment, restructuring and other special charges divided by revenue
[2] 2025 assumes shares outstanding of approximately 900.6 million
IPR&D = in-process research and development
FX assumptions of 1.06 (Euro), 152 (Yen) and 7.1 (Yuan)

Orforglipron ACHIEVE-1 Topline Results

HbA1c and Body Weight Change at 40 Weeks



Key Highlights:

First small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6%

More than 65% of participants taking the highest dose of orforglipron achieved an A1C less than or equal to 6.5%

Once-daily oral pill reduced weight by an average of 16.0 lbs (7.9%) at the highest dose

Participants had not yet reached a weight plateau by the 40-week endpoint

Orforglipron ACHIEVE-1 Safety & Tolerability

Discontinuation Rates due to Adverse Events



Tolerability Data

	Placebo	Orforglipron 3 mg	Orforglipron 12 mg	Orforglipron 36 mg
Nausea (%)	2%	13%	18%	16%
Vomiting (%)	1%	5%	7%	14%
Diarrhea (%)	9%	19%	21%	26%

The overall safety profile of orforglipron in ACHIEVE-1 was consistent with the established GLP-1 class. Treatment discontinuations due to adverse events were low and consistent with the injectable GLP-1 class.

Orforglipron Global Development Program

ACHIEVE Type 2 Diabetes Program and ATTAIN Obesity Program



Expected Submissions

Obesity: Q4 2025

T2D: 1H 2026

Additional Trials

Hypertension: Starting Q2 2025

OSA: Completing Q4 2026

Maintenance: Completing Q1 2026

[a]Event-driven trial, minimum duration 104 weeks; [b]2-year extension for participants with prediabetes.
CV=cardiovascular; HTN=hypertension; OAM=oral anti-hyperglycemic medication; OSA=obstructive sleep apnea; T2D=type 2 diabetes.

Lilly Select NME and NILEX Pipeline

April 29, 2025

NME
NILEX

UPDATES SINCE FEBRUARY 4, 2025
REMOVAL
ADDITION OR MILESTONE ACHIEVED

PHASE 1		PHASE 2		PHASE 3		REG REVIEW	APPROVED
PI3Kα INH (STX-478) *Cancer*	TARGETS UNDISCLOSED *Six Additional NMEs*	CD19 ANTIBODY *Rheumatoid Arthritis*		OLOMORASIB *Adj KRAS G12C+ NSCLC (resected)*			
FXR AG (FXR314) *Immunology*	INTEGRIN α5β1 *CMH*	TIRZEPATIDE *Higher Doses*	TIRZEPATIDE *MASH*	TIRZEPATIDE *CV Outcomes*	TIRZEPATIDE *MMO*		
SNCA siRNA *Neurodegeneration*	ANTI-VEGF GENE THERAPY *Vestibular Schwannoma*	GBA1 GENE THERAPY *Gaucher Disease Type 1*	MORF-057 *Crohn's Disease*	RETATRUTIDE *Diabetes*	SELPERCATINIB *Adjuvant RET+ NSCLC*		
SCAP siRNA *MASH*	SMARCA2 (BRM) *Cancer*	SOLBINSIRAN *CVD*	ELTREKIBART *Ulcerative Colitis*	PIRTOBRUTINIB *R/R MCL Monotherapy*	RETATRUTIDE *CV / Renal Outcomes*		
PNPLA3 siRNA *MASH*	SARM1 INHIBITOR *Neurodegeneration*	P2X7 INHIBITOR *Pain*	SIMEPDEKINRA *Psoriasis*	PIRTOBRUTINIB *1L CLL Monotherapy*	PIRTOBRUTINIB *R/R CLL Combination*		
NISOTIROSTIDE *Diabetes*	PAN KRAS *Cancer*	OCADUSERTIB *Rheumatoid Arthritis*	OTOF GENE THERAPY *Hearing Loss*	ORFORGLIPRON *Diabetes*	ORFORGLIPRON *Obstructive Sleep Apnea*		
NECTIN-4 ADC 1 *Cancer*	NECTIN-4 ADC 2 *Cancer*	MORF-057 *Ulcerative Colitis*	MUVALAPLIN *ASCVD*	LEBRIKIZUMAB *CRSwNP*	OLOMORASIB *1L KRAS G12C+ NSCLC (PD-L1 high)*		
MACUPATIDE *CMH*	MAPT siRNA *Neurodegeneration*	MAZISOTINE *Pain*	MEVIDALEN *AD Symptomatic*	IXEKIZUMAB + TIRZEPATIDE *PsA*	LEBRIKIZUMAB *AR (perennial allergens)*		
KRAS G12D *Cancer*	LA-ANP *Heart Failure*	MAZDUTIDE[1] *Obesity*	KV1.3 ANTAGONIST *Psoriasis*	IMLUNESTRANT *Adjuvant Breast Cancer*	IXEKIZUMAB + TIRZEPATIDE *Psoriasis*		
GS INSULIN RECEPTOR AGONIST *Diabetes*	ITACONATE MIMETIC *Immunology*	GLP-1R NPA II *Obesity*	GRN GENE THERAPY *Frontotemporal Dementia*	ABEMACICLIB *MBC Sequencing*	DONANEMAB *Preclinical Alzheimer's Disease*		
GIP/GLP-1 COAGONIST III *CMH*	GIPR AGONIST LA *CMH*	EPIREGULIN Ab *Pain*	GBA1 GENE THERAPY *Parkinson's Disease*	REMTERNETUG *Alzheimer's Disease*	RETATRUTIDE *Obesity, OA, OSA*		
FGFR3 SELECTIVE *Cancer*	FRa ADC *Cancer*	ELORALINTIDE *Obesity*	ELTREKIBART *Hidradenitis Suppurativa*	OLOMORASIB *1L KRAS G12C+ NSCLC (All PD-L1)*	ORFORGLIPRON *Obesity*	TIRZEPATIDE *Heart Failure pEF*	
[Ac-225]-PSMA-62 *Prostate Cancer*	AT2R ANTAGONIST *Pain*	BIMAGRUMAB *Obesity*	CD19 ANTIBODY *Multiple Sclerosis*	INSULIN EFSITORA ALFA *Diabetes*	LEPODISIRAN *ASCVD*	IMLUNESTRANT *ER+ HER2- mBC*	PIRTOBRUTINIB *R/R CLL Monotherapy*

[1]China development with Innovent for Obesity (reg review) and T2D (Ph3)

Not for promotional use

Potential Key Events 2025

NEW SINCE LAST UPDATE

PHASE 3 INITIATIONS

- Orforglipron for hypertension
- ✓+ Olomorasib for resected adjuvant NSCLC[1]
- Muvalaplin for ASCVD[2]
- Retatrutide for obesity and chronic low back pain

PHASE 3 DATA DISCLOSURES

- Orforglipron for obesity [ATTAIN-1/2]
- Orforglipron for type 2 diabetes [ACHIEVE-1 ✓+ /2/3/4/5]
- Tirzepatide cardiovascular outcomes [SURPASS-CVOT]
- Pirtobrutinib 1L CLL vs. BR[3] [BRUIN CLL-313]
- Pirtobrutinib 1L CLL vs. ibrutinib [BRUIN CLL-314]
- Retatrutide for obesity and OA[4] of the knee [TRIUMPH-4]

REGULATORY SUBMISSIONS

- Insulin efsitora alfa for type 2 diabetes [US/EU/J]
- Orforglipron for obesity [US/EU/J]
- Tirzepatide for cardiovascular outcomes [US]
- Pirtobrutinib CLL full approval [US ✓+]
- Pirtobrutinib for 1L CLL [US/EU]

REGULATORY ACTIONS

- ✓+ Mirikizumab for Crohn's disease [US ✓+ / EU ✓+ / J ✓+]
- Tirzepatide for HFpEF [US ✓- /EU]
- Imlunestrant ER+, HER2- mBC [US/J]
- Pirtobrutinib for CLL full approval [US / EU ✓+ / J]
- Donanemab for early Alzheimer's disease [EU]

[1] Non-small cell lung cancer
[2] Atherosclerotic cardiovascular disease
[3] Bendamustine plus Rituximab
[4] Osteoarthritis

Supplemental Slides

2025 Income Statement – Reported

Dollars in millions; except per share data

	Q1 2025	Change
TOTAL REVENUE	**$12,729**	45%
GROSS MARGIN	**82.5%**	1.6pp
TOTAL OPERATING EXPENSE*	**$6,809**	48%
OPERATING INCOME	**$3,695**	47%
OPERATING MARGIN	**29.0%**	0.4pp
OTHER INCOME (EXPENSE)	**$(239)**	NM
EFFECTIVE TAX RATE	**20.2%**	8.6pp
NET INCOME	**$2,759**	23%
EPS	**$3.06**	23%

* Includes research and development expense; marketing, selling and administrative; acquired in-process research and development charges; and asset impairment, restructuring and other special charges (as applicable)
NM = not meaningful

EPS Reconciliation

	Q1 2025	Q1 2024	% Change
EARNINGS PER SHARE (REPORTED)	$3.06	$2.48	23%
ASSET IMPAIRMENT, RESTRUCTURING AND OTHER SPECIAL CHARGES	0.03	–	NM
NET LOSSES (GAINS) ON INVESTMENTS IN EQUITY SECURITIES	0.13	(0.02)	NM
AMORTIZATION OF INTANGIBLE ASSETS	0.11	0.12	(8%)
EARNINGS PER SHARE (NON-GAAP)	$3.34	$2.58	29%
ACQUIRED IPR&D	$1.72	$0.10	NM

Numbers may not add due to rounding; see slide 21 for more details on these adjustments; NM = not meaningful

Q1 Non-GAAP Adjustments

Q1 2025 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $123 million (pre-tax), or $0.11 per share (after-tax)
- net losses on investments in equity securities totaling $152 million (pre-tax), or $0.13 per share (after-tax)
- asset impairment, restructuring and other special charges related to intangible asset impairment totaling $35 million (pre-tax), or $0.03 per share (after-tax).

Q1 2024 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $139.1 million (pre-tax), or $0.12 per share (after-tax)
- net gains on investments in equity securities totaling $23.4 million (pre-tax), or ($0.02) per share (after-tax).

Q1 2025 Mounjaro Sales Increased $2.0B

$ in Millions

U.S. sales were $2.7 billion
International sales were $1.2 billion



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data March 28, 2025; RA = rolling average
TRx data is representative of the injectable incretin type 2 diabetes market

Q1 2025 Zepbound Sales Increased $1.8B

$ in Millions

U.S. sales were $2.3 billion
International sales were $6 million[1]



U.S. TRx SOM and Market Volume



[1] Japan marketing authorization approved for obesity under the brand name Zepbound

Source: IQVIA NPA TRx 3MMA, weekly data March 28, 2025; RA = rolling average
TRx data is representative of the branded anti-obesity market

Q1 2025 Verzenio Sales Increased 10%

$ in Millions

U.S. sales increased 3%
International sales increased 22%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data March 28, 2025; RA = rolling average

Select Trials – Donanemab

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04437511	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	3	1736	Change from Baseline on the integrated Alzheimer's Disease Rating Scale (iADRS)	Apr 2023	Aug 2025
NCT05738486	Alzheimer's Disease	A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)	3	800	Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)	May 2024	May 2025
NCT05508789	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)	3	1500	Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)	Apr 2027	Apr 2027
NCT05026866	Alzheimer's Disease	A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	3	2196	Time to clinical progression as measured by Clinical Dementia Rating - Global Score (CDR-GS)	Nov 2027	Nov 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Imlunestrant

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04975308	Breast Neoplasms	A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)	3	866	Progression Free Survival (PFS) in the Intent-to-Treat (IIT) Population	Jun 2024	Aug 2027
NCT05514054	Breast Neoplasms	A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)	3	8000	Invasive Disease-Free Survival (IDFS)	Oct 2027	Mar 2032

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Lebrikizumab

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05372419	Atopic Dermatitis	A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color (ADmirable)	3	80	Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) (≥75% reduction from baseline in EASI)	May 2024	Feb 2025
NCT04392154	Atopic Dermatitis	Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)	3	1188	Percentage of Participants Discontinued from Study Treatment due to Adverse Events through the Last Treatment Visit	Jun 2024	Apr 2025
NCT05559359	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)	3	360	Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) ≥75% Reduction from Baseline in EASI Score	Feb 2026	Feb 2027
NCT05735483	Atopic Dermatitis	A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)	3	310	Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs)	Jun 2026	Jun 2026
NCT06280716	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis (ADvance-Asia)	3	430	Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) ≥75% Reduction from Baseline in EASI Score	Dec 2025	Nov 2026
NCT06339008	Perennial Allergic Rhinitis (PAR)	A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)	3	450	Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at week 16	Oct 2025	Feb 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Lebrikizumab (Cont.)

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06921759	Atopic Hand and Foot Dermatitis	A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis	3	206	Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from Baseline	Jul 2026	Sep 2026
NCT06338995	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	3	510	Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity	Oct 2026	Feb 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Lepodisiran

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06292013	Atherosclerotic Cardiovascular Disease (ASCVD)[1]	A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) -ACCLAIM-Lp(a)	3	12500	Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint	Mar 2029	Mar 2029

[1] Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD)

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Mirikizumab

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04232553	Crohn's Disease	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)	3	778	Percentage of Participants Achieving Endoscopic Response	Nov 2024	Dec 2026
NCT06937099	Crohn's Disease	Mirikizumab and Tirzepatide Concomitantly Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (COMMIT-CD)	3	290	Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI)	May 2028	May 2028
NCT03519945	Ulcerative Colitis	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-3)	3	1063	Percentage of Participants in Clinical Remission	Jul 2026	Dec 2027
NCT06937086	Ulcerative Colitis	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight (COMMIT-UC)	3	350	Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction	Apr 2028	Apr 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Olomorasib

Source: clinicaltrials.gov, April 23, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06119581	Carcinoma, Non-Small-Cell Lung	A Study of olomorasib (LY3537982) Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)	3	1016	Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)	Oct 2026	Oct 2029
NCT06890598	Carcinoma, Non-Small-Cell Lung	Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)	3	700	Part A: Disease-Free Survival (DFS) by Investigator Assessment, DFS by Investigator Assessment, Randomization to disease recurrence or death from any cause (Estimated as approximately 48 months). Part B: Progression-Free Survival (PFS), PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR), Randomization to disease progression or death from any cause (Estimated as approximately 3 years).	May 2029	Feb 2032
NCT04956640[1]	Carcinoma, Non-Small-Cell Lung	Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)	1|2	540	Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy	Apr 2027	Apr 2027

[1] Also lists Merck Sharp & Dohme LLC

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Orforglipron

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06010004	Type 2 Diabetes	A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes (ACHIEVE-J)	3	399	Number of Participants with Treatment Emergent Adverse Events (TEAEs)	Jun 2025	Jun 2025
NCT06109311	Type 2 Diabetes	A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)	3	520	Change from Baseline in Hemoglobin A1c (HbA1c) Compared to Placebo	Sep 2025	Sep 2025
NCT06045221	Type 2 Diabetes	A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (ACHIEVE-3)	3	1576	Change from Baseline in Hemoglobin A1c (HbA1c)	Sep 2025	Sep 2025
NCT05803421	Type 2 Diabetes	A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)	3	2749	Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]	Sep 2025	Jan 2026
NCT06192108	Type 2 Diabetes	A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)	3	888	Change from Baseline in Hemoglobin A1c (HbA1c)	Sep 2025	Sep 2025
NCT05931380	Obesity	A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease (ATTAIN-J)	3	236	Mean Percent Change in Body Weight	Jun 2025	Jul 2025

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Orforglipron (Cont.)

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05869903	Obesity	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)	3	3000	Mean Percent Change from Baseline in Body Weight	Jul 2025	Jul 2027
NCT05872620	Obesity	A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)	3	1500	Mean Percent Change from Baseline in Body Weight	Aug 2025	Aug 2025
NCT06584916	Obesity	A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)	3	300	Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5	Jan 2026	Jan 2026
NCT06672939	Obesity	A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities	3	125	Percent Change from Baseline in Body Mass Index	Feb 2027	Mar 2027
NCT06649045	OSA	A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA)	3	600	Change from Baseline in Apnea-Hypopnea Index (AHI)	Nov 2026	Jan 2027
NCT06824051	Obesity	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight	1	120	Percent Change from Baseline in Visceral Adipose Tissue (VAT)	Dec 2025	Dec 2025

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Pirtobrutinib

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04666038	Chronic Lymphocytic Leukemia	Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)	3	238	To evaluate progression-free survival (PFS) of LOXO-305 monotherapy (Arm A) compared to investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) (Arm B)	Aug 2023	May 2027
NCT05023980	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)	3	250	To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)	May 2025	Aug 2026
NCT04965493	Chronic Lymphocytic Leukemia	A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)	3	600	To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)	Apr 2026	Jan 2027
NCT05254743	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With BTK naïve Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-314)	3	650	Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR)	Jun 2025	Jan 2028
NCT04662255	Lymphoma, Mantle-Cell	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN MCL-321)	3	500	To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)	Jan 2027	Apr 2028
NCT06721013	Immune Thrombocytopenia (ITP)	A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia	1|2	58	Phase 1-Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Feb 2027	Feb 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Remternetug

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05463731	Alzheimer's Disease	A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)	3	1667	Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus Placebo	Apr 2024	Mar 2026
NCT06653153	Alzheimer's Disease	A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)	3	1200	Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate (CDR)	Apr 2029	Oct 2030

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Retatrutide

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05929066	Obesity	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)	3	2300	Percent Change From Baseline in Body Weight	Apr 2026	May 2026
NCT05929079	Obesity	A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)	3	1000	Percent Change from Baseline in Body Weight	May 2026	May 2026
NCT05882045	Obesity	A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)	3	1800	Percent Change from Baseline in Body Weight	Jan 2026	Feb 2026
NCT05931367	Obesity	A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4)	3	405	Percent Change from Baseline in Body Weight and Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score	Dec 2025	Dec 2025
NCT06383390	Obesity	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)	3	10000	Time to First Occurrence of Composite Endpoints, A composite endpoint includes nonfatal myocardial infarction (MI), nonfatal stroke, cardiovascular (CV) death, or hospitalization or urgent visit due to heart failure (HF) Time to First Occurrence of Composite Endpoint of End Stage Kidney Disease (ESKD), ≥ 40% Sustained Decline in Estimated Glomerular Filtration Rate (eGFR), CV Death or Renal Death	Feb 2029	Feb 2029

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Retatrutide (Cont.)

Source: clinicaltrials.gov, April 24, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06662383	Obesity	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)	3	800	Percent Change from Baseline in Body Weight, Baseline, Week 80	Dec 2026	Dec 2026
NCT06859268	Obesity	A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity (TRIUMPH-6)	3	586	Percent Change from Baseline in Body Weight	Apr 2028	Apr 2028
NCT05936151	Chronic Kidney Disease	A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	2	120	Change from Baseline in Glomerular Filtration Rate (mGFR)	Nov 2025	Nov 2025
NCT06354660	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)	3	480	Change from Baseline in Hemoglobin A1c (HbA1c)	Jan 2026	Feb 2026
NCT06297603	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)	3	320	Change from Baseline in Hemoglobin A1c (HbA1c)	Sep 2026	Oct 2026
NCT06260722	Type 2 Diabetes	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	3	1250	Change from Baseline in Hemoglobin A1c (HbA1c)	Aug 2026	Jan 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Retevmo

Source: clinicaltrials.gov, April 24, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04211337	Medullary Thyroid Cancer	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	3	291	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)	May 2023	Feb 2026
NCT04194944	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)	3	261	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with Pembrolizumab)	May 2023	Jun 2026
NCT03157128	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)	1|2	857	Phase 1: MTD, Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment, The first 28 days of treatment (Cycle 1)	Feb 2025	Feb 2026
NCT04819100	Carcinoma, Non-Small-Cell Lung	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)	3	152	Event-Free Survival (EFS), EFS by Investigator Assessment in the Primary Analysis Population, Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years)	May 2026	May 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Taltz

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06588283	Psoriasis	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO)	3	250	Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction	Dec 2025	May 2026
NCT06588296	Psoriatic Arthritis	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA)	3	250	Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction	Apr 2026	Aug 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Tirzepatide

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06047548	Obesity	A Study of Tirzepatide (LY3298176) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)	3	400	Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period	May 2026	May 2026
NCT06075667	Obesity	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS)	3	150	Percent Change from Baseline in Body Mass Index (BMI)	Oct 2026	Oct 2026
NCT06439277	Obesity	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	3	300	Percent Change from Baseline in Body Mass Index (BMI)	May 2027	Jun 2027
NCT05556512	Obesity	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)	3	15374	Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events)	Oct 2027	Oct 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Tirzepatide (Cont.)

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04255433	Type 2 Diabetes	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)	3	13299	Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke (MACE-3)	Jun 2025	Jun 2025
NCT06037252	Type 2 Diabetes	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	2	350	Percent Change From Baseline in Body Weight	Jan 2026	Oct 2026
NCT05536804	CKD	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREASURE-CKD)	2	140	Change from Baseline in Kidney Oxygenation in Participants With or Without T2D [Time Frame: Baseline, Week 52]; Blood oxygenation-level dependent magnetic resonance imaging (BOLD MRI)	Sep 2026	Oct 2026
NCT06914895	Type 1 Diabetes	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight	3	905	Change from Baseline in Hemoglobin A1c (HbA1c)	May 2027	May 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Verzenio

Source: clinicaltrials.gov, April 22, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03155997[1]	Breast Cancer	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)	3	5637	Invasive Disease-Free Survival (IDFS)	Mar 2020	May 2029
NCT05169567	Breast Neoplasm	Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMonarch)	3	368	Progression-Free Survival (PFS)	Feb 2024	Feb 2026

[1] Also lists NSABP Foundation Inc

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Cardiometabolic Health

Source: clinicaltrials.gov, April 22, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Bimagrumab	NCT05616013	Obesity	Safety and Efficacy of Bimagrumab and Semaglutide in Adults who are Overweight or Obese	2	507	Change from baseline in body weight at 48 weeks	May 2024	Jun 2025
Bimagrumab	NCT06643728	Obesity	A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight	2	240	Percent Change from Baseline in Body Weight, Baseline, Week 24	Apr 2026	Jan 2027
Bimagrumab	NCT06901349	Obesity	A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes	2	180	Percent Change from Baseline in Body Weight, Baseline, Week 36	Oct 2026	Jan 2027
Eloralintide	NCT06230523	Obesity	A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight	2	250	Percent Change from Baseline in Body Weight	Jun 2025	Sep 2025
Eloralintide	NCT06603571	Obesity	A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes	2	350	Percent Change from Baseline in Body Weight	Jun 2026	Aug 2026
Eloralintide	NCT06916091	Obesity	A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight	1	36	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Aug 2025	Aug 2025

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Cardiometabolic Health (Cont.)

Source: clinicaltrials.gov, April 24,2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
GIP/GLP-1 Coagonist III	**NCT06606106**	Healthy	A Study of LY3537031 in Overweight, Obese, and Healthy Participants	1	230	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration	Jul 2026	Jul 2026
GLP-1R NPA II	**NCT06683508**	Obesity	A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight	2	275	Percent Change from Baseline in Body Weight	Apr 2026	Sep 2026
GS Insulin Receptor Agonist	**NCT06280703**	Healthy	A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)	1	70	Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Aug 2025	Aug 2025
LA-ANP	**NCT06148272**	Healthy	A Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension	1	225	Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Jun 2025	Jun 2025

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Cardiometabolic Health (Cont.)

Source: clinicaltrials.gov, April 22,2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Macupatide	NCT06557356	Obesity	A Study of LY3532226 in Participants With Obesity	1	105	Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	May 2025	May 2025
Mazdutide	NCT06124807	Obesity	A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight	2	179	Percent Change from Baseline in Body Weight	Jan 2025	May 2025
Mazdutide	NCT06817356	Alcohol Use Disorder	A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder	2	300	Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method	Aug 2026	Aug 2026
Nisotirostide	NCT06897475	Type 2 Diabetes	A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	2	240	Change from Baseline in Hemoglobin A1c (HbA1c), Baseline, Week 24	Dec 2026	Jan 2027
PNPLA3 siRNA	NCT05395481	Non-Alcoholic Fatty Liver Disease	A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease	1	176	Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Oct 2026	Oct 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Immunology

Source: clinicaltrials.gov, April 25, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
CD19 Antibody	NCT06220669	Multiple Sclerosis	A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis	2	200	Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions	Aug 2027	Aug 2028
CD19 Antibody	NCT06859294	Rheumatoid Arthritis	A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis	2	40	Change from Baseline in Disease Activity Score - High-Sensitivity C-Reactive Protein (DAS28 - hsCRP)	Feb 2026	Sep 2026
SIMEPDEKINRA (DC-853)	NCT06602219	Plaque Psoriasis	A Study of LY4100511 (Dice 853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis	2	220	Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75	Jul 2025	Aug 2025
Eltrekibart	NCT06046729	Hidradenitis Suppurativa	A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	2	350	Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)	Aug 2025	Jul 2026
Eltrekibart	NCT06598943	Ulcerative Colitis	A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis	2	140	Percentage of Participants Achieving Clinical Remission	Dec 2027	Sep 2028
Itaconate Mimetic	NCT06153355	Healthy	A First-In-Human Study of LY3839840 in Healthy Participants	1	178	Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	May 2025	May 2025

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Immunology (Cont.)

Source: clinicaltrials.gov, April 22, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
KV1.3 Antagonist	**NCT06176768**	Plaque Psoriasis	A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis	2	75	Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI 75)	Apr 2025	Jul 2025
MORF-057	**NCT05611671**	Ulcerative Colitis	A Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC (EMERALD-2)	2	282	Proportion of participants in clinical remission at Week 12 as determined using the Modified Mayo Clinic Score (mMCS)	Nov 2024	Aug 2026
MORF-057	**NCT06226883**	Crohn's Disease	A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)	2	210	Proportion of participants with endoscopic response at Week 14 determined using the Simple Endoscopic Score-CD (SES-CD)	May 2026	Jun 2028
Ocadusertib[1]	**NCT05848258**	Rheumatoid Arthritis	An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis	2	380	Phase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)	Feb 2026	Jul 2026

[1] Also lists Rigel Pharmaceuticals

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Neurodegeneration

Source: clinicaltrials.gov, April 22, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Anti-VEGF Gene Therapy	**NCT06517888**	Vestibular Schwannoma	A Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals with Unilateral Vestibular Schwannoma	1|2	27	AEs with relationship to the investigational medicinal product and/or to the administration procedure (including the delivery device)	Aug 2029	Aug 2029
GBA1 Gene Therapy	**NCT04127578**	Parkinson's Disease	Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)	1|2	20	Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Dec 2030	Dec 2030
GBA1 Gene Therapy	**NCT05487599**	Gaucher Disease	A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)	1|2	15	Incidence and severity of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Oct 2030	Oct 2030
GRN Gene Therapy	**NCT04408625**	Frontotemporal Dementia	Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) (PROCLAIM)	1|2	30	Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuation	Apr 2030	Apr 2030

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Neurodegeneration (Cont.)

Source: clinicaltrials.gov, April 22, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
MAPT siRNA	**NCT06297590**	Alzheimer's Disease	A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease	1	32	Part A: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Feb 2027	Feb 2027
Mevidalen	**NCT06538116**	Alzheimer's Disease	A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease	2	300	Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)	Dec 2025	Jan 2026
OTOF Gene Therapy	**NCT05821959**	OTOF - mediated hearing loss	Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss	1|2	14	Frequency of Adverse Events (AEs)	Oct 2028	Oct 2028
SARM1 CNS Inhibitor	**NCT05492201**	Healthy	A Study of LY3873862 in Healthy Participants	1	84	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Jun 2025	Jun 2025
SNCA siRNA	**NCT06565195**	Parkinson's Disease	A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease (PROSPECT)	1	108	Incidence of Serious Adverse Events (SAEs)	May 2029	May 2029

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Oncology

Source: clinicaltrials.gov, April 23, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
225Ac-PSMA-62	NCT06229366	Prostate Cancer	[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL)	1	142	Maximum tolerated dose (MTD), Phase 1a: Incidence of dose limiting toxicities (DLTs), From first dose of study drug through end of DLT period (4 weeks)	Sep 2027	Dec 2032
FGFR3 Selective	NCT05614739	Urinary Bladder Neoplasms	A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 (FORAGER-1)	1	535	Phase 1a: To determine the recommended dose of LOXO-435: Safety, number of participants with dose-limiting toxicities (DLTs)	Jun 2027	Jun 2027
Fra ADC (FOLR1 ADC)	NCT06400472	Ovarian Neoplasms	A Study of LY4170156 in Participants With Selected Advanced Solid Tumors	1	360	Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156, Number of participants with dose-limiting toxicities (DLTs)	Feb 2027	Apr 2027
KRAS G12D	NCT06586515	Pancreatic Ductal Adenocarcinoma	A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors (MOONRAY-01)	1	540	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Mar 2029	Mar 2029
Nectin-4 ADC 1	NCT06238479	Metastatic Solid Tumor	A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (EXCEED)	1	490	Phase 1a: To determine the recommended dose of LY4101174: Number of participants with dose-limiting toxicities (DLTs)	Mar 2027	Mar 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Oncology (Cont.)

Source: clinicaltrials.gov, April 22, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
PAN KRAS	NCT06607185	Pancreatic Ductal Adenocarcinoma	A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors	1	750	Number of Participants with Dose-limiting Toxicities (DLTs)	Jan 2030	Jan 2030
SMARCA2 (BRM)	NCT06561685	Metastatic Solid Tumor	A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors	1	160	Phase 1a: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs)	Oct 2027	Oct 2027
STX-478	NCT05768139	Breast Cancer	First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors	1|2	400	Percentage of the Total Radioactive Dose in Urinary, Fecal, and Urinary and Fecal Combined Excretion	Feb 2027	Feb 2029

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Pain

Source: clinicaltrials.gov, April 22, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Epiregulin Ab	NCT06568042	Neuropathic Pain	Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy	2	450	Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)	Jun 2026	Sep 2026
Mazisotine	NCT06074562	Diabetic Peripheral Neuropathy	A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain	2	410	Mean Change from Baseline for Average Pain Intensity Numeric Rating Scale (API-NRS)	Jul 2025	Jul 2025

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Trademarks

All trademarks and trade names referred to in this earnings update are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this earnings update, the property of their respective owners. Solely for convenience, the trademarks and trade names in this earnings update are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.